Introduction
Nifedipine and other dihydropyridine calcium channel blockers (CCBs) are widely used in the treatment of hypertension, ischemic heart disease and cardiac failure with preserved left ventricular systolic function (1) (2) (3) (4) (5) (6) . Nifedipine is also used in the treatment of aortic valve incompetence (7) and pulmonary hypertension (8) . These drugs are effective in lowering arterial pressure, relieving myocardial ischemia, and improving both systolic and diastolic left ventricular function (3, 4, 9) . Their beneficial effects have been attributed to peripheral arteriolar dilation, which results in decreases in mean arterial pressure and left ventricular afterload (5, 9) . However, there have been few studies on the effects of nifedipine on pulsatile phenomena, either in the systemic or pulmonary circulations. While nifedipine has been shown to reduce early wave reflection and central aortic systolic pressure (10) , the limited studies of vascular impedance have not shown a consistent effect of the drug on the frequency-dependent components of ascending aortic impedance (11, 12) . And despite the drug's use in pulmonary hypertension (8) , no data are available on the effects of nifedipine on pulmonary vascular impedance.
The purpose of this study was to investigate the effects of nifedipine on pulsatile arterial hemodynamics and systemic and pulmonary vascular impedance in human subjects undergoing cardiac catheterization for known or suspected ischemic heart disease.
Methods

Patients
Twelve patients underwent diagnostic cardiac catheterization for chest pain syndromes at our institution over the study period; five had suffered from myocardial infarction, six had experienced angina pectoris, and one was subsequently diagnosed with neurocirculatory asthenia. No patient had clinical or catheterization evidence of pulmonary disease, valvular disease or heart failure. Vasoactive medications were discontinued 24-h before cardiac catheterization. The study protocol and all procedures were approved by the ethical review committee of Jichi Medical University School of Medicine.
All studies were performed in a fasting, post-absorptive state after premedication with Diazepam 10 mg by intramuscular injection. Routine right-heart catheterization was performed using an antecubital vein cutdown approach. Leftheart catheterization was performed using a brachial artery cutdown approach. After routine coronary angiography and left ventriculography, the standard catheters were replaced by custom-designed high-fidelity transducer catheters (Millar Instruments, Houston, USA) (Fig. 1) .
The right heart catheter was a #8 F catheter with a #6 F leader that was advanced into either the right or left pulmonary artery. The leader helped to stabilize the catheter. Pressure and flow velocity sensors were located 5.5 cm back from the tip to allow measurement of the main pulmonary artery pressure and flow velocity. A second pressure transducer was located 5 cm further back to allow simultaneous measurement of right ventricular pressure. The #8 F arterial catheter had a pressure transducer located at the tip. The catheter tip was advanced across the aortic valve to help stabilize the catheter and to keep the sensors in the center of the stream, while also allowing measurement of left ventricular pressure. Pressure and flow velocity sensors were located 5 cm back from the tip to allow measurement of ascending aortic pressure and flow velocity (Fig. 1) . The pulmonary artery and aortic flow velocity sensors were connected to two identical Biotronex BL-613 flow meters (Biotronex Laboratories, Chester, USA) whose signals were amplified by two identical, specially constructed, non-inverting operational amplifiers. Each system had a phase lag of 1.3°/Hz, which was accounted for in subsequent calculations.
Before inserting each catheter, the sensors were prewarmed for at least 30 min in saline solution at 37°C. The pressure reading at the end of this period, with the pressure sensor barely submerged in the fluid at atmospheric pressure, was used as the zero pressure reference signal of the study. The flow velocity signals were low-pass-filtered with corner frequencies at 50 Hz. The flow velocity signals together with the four pressure signals and surface ECG were recorded on a TEAC 71 seven-channel analogue magnetic tape recorder (TEAC Corporation, Tokyo, Japan) for subsequent analysis and also on an Electronics for Medicine VR16 recorder (Honeywell, Freeport, USA) as a reference. All signals were fed into a SANEI signal processor 7T17 (Sanei, Tokyo, Japan) to calculate the input resistance, pressure/flow moduli, and phase spectrum by Fourier analysis. The ascending aortic cross-sectional area was estimated by measuring the diameter of the aorta (averaged over a cardiac cycle and both before and after administration of nifedipine) at the upper margin of the sinus of Valsalva. Aortic mean flow was calculated from the flow velocity signal, together with the aortic root area determined from aortic diameter. The correlation between the stroke volume derived from the thermodilution method and that from the aortic flow signal was high (r= 0.97) (12) , but the stroke volume determined from the pulmonary flow velocity probe was somewhat smaller than that determined by thermodilution.
Protocol
Each catheter was manipulated to obtain an optimal flow velocity signal characterized by a steady diastolic level with maximal systolic amplitude and minimal late systolic negative flow. The aim was to position the catheter in the center of the vessel where the velocity profile is relatively flat. Pressure and flow were recorded with the patient resting quietly and breathing shallowly. This initial period, which followed the last injection of contrast material by at least 20 min, constituted the baseline condition. Nifedipine 10 mg was administered sublingually as the contents of a single capsule. After 20-30 min, when the pulmonary artery and left ventricular pressures had reached a steady state, the recordings were repeated.
Calculation and Data Analysis
Aortic pressure and velocity signals were digitized at a sampling interval of 5 ms. The digitized flow velocity signals were displayed on the terminal screen and only beats that had negligible baseline drift and negligible negative dip or secondary rise in diastole were considered acceptable for analysis. Zero flow was assumed to be that in late diastole. The calibration of the flow velocity probes was performed as previously reported (13) (see above). From the calibrated flow velocity, the aortic volume flow at desired times in the study was calculated by multiplying by aortic cross-sectional area.
The main pulmonary artery diameter could not be reliably measured, so the mean pulmonary artery volume flow was assumed to be equal to the mean aortic volume flow. The input impedance modulus (Zn) and phase angle for each harmonic were calculated as the ratio of the pressure to the flow moduli and the difference of the pressure and flow phase angles, respectively (10). The input resistance, which was the impedance of 0 Hz, was calculated as the mean pressure divided by the mean flow. Pulmonary vascular resistance was calculated as the pulmonary artery pressure divided by the cardiac output. The characteristic impedance (Zc) was estimated by averaging the impedance moduli in the frequency range of 2-8 Hz (10, 13) . A measure of the reflection characteristics of each vascular bed was obtained by calculating the difference in moduli for frequencies between 1 and 8 Hz, as
The first zero crossing of the phase angle was obtained by linear interpolation. For impedance determination, results were averaged over 6-8 pulses to cover one respiratory cycle. Augmentation of the ascending aortic pressure pulse was calculated as the pressure rise from the first systolic shoulder to the peak of the wave, and was expressed in mmHg, and augmentation index was expressed as a percentage of the pulse pressure (10) . An effect was considered to be significant at the p= 0.05 level. Data are presented as the mean±SD. Comparisons between before and after administration of nifedipine were made using paired Student's t-test. Zn Zc -( )
Results
The clinical characteristics of the twelve patients are given in Table 1 , and the basic hemodynamic data under control conditions are given in Table 2 . All patients were male with an average age of 55.4±6.3 years (age range 43-63 years).
Representative tracings of pressure and flow recorded simultaneously in the left and right ventricles, and in the aorta and pulmonary arteries are shown in Fig. 2 , before and after administration of nifedipine. The averaged values of hemodynamic parameters in all patients before and after nifedipine administration are given in Table 3 .
Nifedipine administration led to an increase in heart rate from 70 to 84 beats per min (bpm), as well as an increase in stroke volume and, consequently, an even greater (31%) increase in cardiac output. Nifedipine administration resulted in a significant reduction in systemic but not pulmonary vascular resistance (from 1,664 to 1,126 dyn s cm
and 241 to 182 dyn s cm − 5 [NS], respectively). There was no significant change in other pulmonary hemodynamic data or in pulmonary vascular impedance with nifedipine, but there was a very clear change in the systemic vascular impedance (Fig. 3) . The increase in cardiac output with nifedipine was associated with a decrease in mean pressure from 102 to 90 mmHg, signifying a decrease in peripheral systemic resistance. Accompanying this, there was a fall of 25 mmHg (p< 0.0001) in systolic pressure but only 9 mmHg (p< 0.02) in diastolic pressure. The substantial fall in systolic pressure was associated with and largely caused by a reduction in the amplitude of the late systolic peak (Fig. 2) . Measured aortic systolic pressure wave augmentation was determined as the pressure difference between the first systolic shoulder and the pressure peak (14, 15) . This fell from 22 to 10 mmHg (p< 0.0001). Despite the 8% increase in stroke volume, the pulse pressure actually decreased by 30% (p< 0.0001). Such a decrease in pressure fluctuation despite an increase in flow fluctuation suggests either a decrease in wave reflection or a decrease in arterial stiffness. The change in shape of the pressure wave, with a reduction in augmentation after the first systolic shoulder, suggests a reduction in the peripheral wave reflection (12) (13) (14) . This was supported by the 43% reduction (from 193 to 110 dyn s cm − 5 [p< 0.0001]) of the modulus of impedance 
Fig. 2. Simultaneous recordings of systemic and pulmonary pressure and flow data in a typical patient before (left) and after (right) administration of nifedipine. The top tracing is an ECG, the second tracing represents aortic pressure (AoPr), the third tracing represents left ventricular pressure (LVPr), the fourth tracing represents aortic flow velocity (AoFV), the fifth tracing represents pulmonary flow velocity (PAFV), the sixth tracing represents pulmonary artery pressure (PAPr), and the seventh tracing represents right ventricular pressure (RVPr
Fig. 3. Modulus of impedance in the ascending aorta (left) and main pulmonary artery (right) before (closed circles, solid lines) and after (open circles, dashed lines) administration of nifedipine. Bars: ±SD.
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aorta with the reduction in arterial pressure.
The steady component of external left ventricular work did not increase significantly after nifedipine administration, the increase in cardiac output being offset by a fall in mean pressure. The decrease in impedance modulus more than offset the increase in stroke volume and pulsatile flow, such that the pulsatile component of external work did not change, and neither did the ratio of pulsatile to total external work.
In the pulmonary circulation, mean pressure did not change after administration of nifedipine (15 mmHg both before and after), and neither did characteristic impedance (37 and 33 dyn s cm − 5 before and after). Nifedipine administration did not affect end-diastolic pressure of the left or right ventricle, and did not alter the timing of wave reflection, as gauged by the zero crossing of the impedance phase (Fig. 4) . For the ascending aorta, this frequency was 3.3±0.6 Hz before, and 3.4±0.6 Hz (NS) after nifedipine administration; for the pulmonary artery, this frequency was 2.5±0.8 Hz before, and 2.8±1.2 Hz (NS) after nifedipine. This frequency corresponded to the minimal value of the impedance modulus, but could be measured more accurately.
Discussion
To our knowledge, this paper is the first to simultaneously determine the pulsatile hydraulic load presented to the left and right ventricle, before and after use of an orally effective vasodilator agent in human subjects. Input impedance is composed of three components: resistance (mean pressure ÷ mean flow), stiffness of proximal arteries (ascending aortic or main pulmonary artery characteristic impedance) and reflectance (augmented pressure or impedance fluctuation) (10) . The results are intriguing in that they show no significant effect on pulmonary impedance and right ventricular pulsatile load, but considerable effect on left ventricular pulsatile load. The observed effects on the systemic circulation were largely attributed to the decreased peripheral resistance and decreased wave reflection induced by nifedipine. Ascending aortic impedance is widely accepted as an expression of left ventricular load (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) , and pulmonary vascular impedance as an expression of right ventricular load (27) (28) (29) . Studies have been undertaken in patients with chest pain syndromes but without definite cardiovascular disease, in patients with hypertension, in patients with cardiomyopathy, and in patients such as those described here, with coro- nary atherosclerosis (Table 4) . In past studies of vasodilator action, most attention has been directed to the zero frequency component of impedance modulus-the peripheral resistance. In the late 1970s and early 1980s, the attention began to shift to the changes in characteristic impedance and aortic stiffness resulting from the underlying disease or from drug therapy (16) (17) (18) (19) (20) . The values of the systemic and pulmonary resistance described here are similar to those reported earlier; the values of aortic and pulmonary characteristic impedance are also in the range of those reported before (Table 4) .
In this study we have shown a decrease in peripheral systemic resistance with nifedipine, in association with an increase in cardiac output and fall in systemic arterial pressure. We have shown, however, that these effects occur without any change in pulmonary characteristic impedance and no significant reduction in systemic characteristic impedance.
We have pointed out that the marked falls in systolic pressure and pulse pressure, and the change in shape of the aortic and left ventricular wave contours, cannot be explained solely by the change in mean pressure and characteristic impedance. However, the decrease in systolic and pulse pressure and the change in waveform can readily be explained on the basis of the decrease in the amplitude of the reflected wave returning from peripheral vascular terminations and consequently on peripheral vasodilation (10, 16, 24) . The evidence for this is the reduction in fluctuation of the impedance modulus, and the substantial fall in the ascending aortic impedance modulus at the frequency of the first harmonic of the pulse. Similar changes have been noted with nitroglycerin (23, 24) and with nitroprusside (18) (19) (20) (21) , and have been attributed to a reduction in pressure wave reflection. These effects on wave reflection have been attributed to arteriolar dilation in the case of nitro- (21, 22) , and in the case of nitroglycerin, to a change in the caliber and compliance of the small conduit arteries immediately upstream from the resistive arterioles (10, 23, 24) .
In this study, the change in ascending aortic impedance was associated with a marked reduction in pressure augmentation in the ascending aorta. This fall in augmentation (of 12 mmHg) was of similar magnitude to the degree of fall in mean systemic pressure (12 mmHg) and largely explains the marked reduction in pulse pressure (of 16 mmHg). The reduction of aortic systolic pressure was caused both by a reduction in pressure augmentation and a fall in mean pressure. Both are attributable to peripheral vasodilation, acting in different ways-in the first case through a decrease in wave reflection, and in the second through a decrease in peripheral resistance.
The beneficial therapeutic effects of nifedipine can thus be largely attributed to reductions in the peripheral resistance and wave reflection. In mature adults, high aortic pulse wave velocity, together with structural changes in the region of the abdominal aorta (10, 26, 30) result in wave reflection returning inappropriately early to the heart, and boosting the pressure generated by ventricular ejection in late systole. This pressure boost comprises a substantial component of the left ventricular afterload (10, 13, 14, 31) . Its reduction, such as by nitroprusside administration, leads to a reduction in left ventricular load and an improvement in left ventricular function, especially during exercise in patients with left ventricular failure (32) . The decrease in systolic pressure by this mechanism also partially explains the benefit of this drug in patients with hypertension and angina pectoris (10, 31) .
The effects of nifedipine described here are similar to those previously described for nitroprusside (18, 19, 21, 22) and for nitroglycerin (23, 24) , although unlike nitroglycerin, both nifedipine and nitroprusside consistently decrease peripheral resistance (18, 19, 21) . It has been stressed, however, that the beneficial effects of nitroglycerin and of nitroprusside may be underestimated when pressure is measured in a peripheral artery (8, 10, 33, 34) . The ill effects of early wave reflection, and the beneficial effects of its reduction cannot be properly interpreted or assessed from conventional measurement of the peak (systolic) and lowest (diastolic) pressure in an upper limb artery; they can, however, be assessed from interpretation of the brachial or radial artery pressure wave contour (10, 33, 34) . It is quite likely that the same principles also apply to nifedipine. However, no study has yet been conducted to determine the effects of nifedipine on the differences in pressure wave contour between the central and peripheral arteries.
The results presented here for systemic arterial hemodynamics are in line with the report by Ting et al. (12) , but at variance with those reported by Chang et al. (11) in groups of hypertensive subjects. Chang et al. (11) found a reduction in systemic vascular resistance, and in the steady component of left ventricular work with nifedipine, but were unable to demonstrate any effect on the frequency-dependent components of ascending aortic impedance. They did show a greater reduction in systolic than in diastolic pressure with nifedipine, as well as a reduction in amplitude of the first harmonic component of impedance, and a reduction of pulse pressure, but the latter two effects were not statistically significant. The authors studied just seven patients and may have taken control data close to the time of contrast angiography, when the vasodilating effect of the contrast agent was still in evidence. The fact that cardiac output did not increase in that study raises a question as to whether the drug was exerting a pharmacological effect at the time data were taken, i.e., 10-30 min after sublingual administration. Ting et al. (12) used a higher dose of nifedipine and showed, as did we, reductions in the measures of wave reflection and in the systemic vascular resistance. Ting et al. also showed a reduction in aortic characteristic impedance.
The data presented here are concordant with those of Ting et al. (12) and support the concept that nifedipine is a logical therapeutic agent for management of hypertension or of other conditions (including cardiac failure and coronary disease in older persons) in which the arterial system is stiffened and wave reflection adds to the left ventricular load (24, 31, (34) (35) (36) . However, one caveat should be made in regard to the use of short-acting nifedipine, such as used here-namely, the decrease in vascular resistance may cause coronary steal and/ or tachycardia, which could worsen myocardial ischemia (10) . The ideal antihypertensive agent in isolated systolic hypertension (37) , and the ideal anti-anginal agent (10) may be one which, like nitroglycerin, reduces wave reflection and aortic systolic pressure while maintaining peripheral resistance and mean arterial pressure (10, 24, 33-35, 37, 38) . Long-acting nifedipine is comparable to an angiotensin converting enzyme inhibitor in efficacy and side effect profile (39), and does not induce sympathetic stimulation and tachycardia as can the short-acting preparations used in this study.
